Bangalore News Network
Advertise With BNN
About Us
Bangalore News Network
BNN
Karnataka Elections 2018
Industry & Commerce
Launches
Health
Social Service
Sports
Politics
Fashion & Entertainment
Interviews
Other News
Feedback
Trending News
List All News
Request News Coverage

Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®

AKYNZEO®was developed by Helsinn,and Glenmark has the exclusive marketing rights for the product in India and Nepal under a licensing agreement with Helsinn ** AKYNZEO®, an oral fixed dose combination of netupitant 300mg and palonosetron 0.5mg, is a single capsule that acts on dual pathway and offers 5-day prophylaxis from both the acute and delayed phases of CINV
Bengaluru | Written by: BNN Team | Updated: 10-07-2018 | Views: 194
TRENDING
Industry & Commerce - Sun-AP Ecopower partners US-based OutBack Power Technologies
Others - On the occasion of Kannada Rajyotsava Gopala ...
Others - Diwali celebrations begin on a grand not ...

Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announced the launch of AKYNZEO®, a fixed dose combination drug for the prevention of CINV (chemotherapy-induced nausea and vomiting) in the Indian market under an exclusive licensing agreement.


AKYNZEO®, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg, is to be administered in a single capsule that acts on both the two main pathways associated with acute and delayed phases of CINV. The product has been developed by Helsinn and Glenmark has exclusive marketing rights for AKYNZEO® in India and Nepal.


“Oncology is a key area of focus for Glenmark and we are committed to bringing in new treatment options for Indian patients. Nausea and vomiting associated with chemotherapy has a significant impact on quality of life of cancer patients that can influence a patient’s adherence to the treatments being undertaken. AKYNZEO® is a convenient single-dose oral capsule for each chemotherapy cycle that covers both the acute and delayed phase of CINV, avoiding multiple drug antiemetic options and thereby improving patient compliance,” said Sujesh Vasudevan, President – India Formulations, Middle East and Africa at Glenmark.


Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “We are very pleased to announce that the oral fixed combination AKYNZEO® has now been launched in India and Nepal, providing a new prophylactic option for patients suffering from chemotherapy-induced nausea and vomiting. Helsinn is focused on helping people with cancer get the best out of every day and is pleased to be expanding its availability. Glenmark is a trusted partner with an excellent footprint in this region and a commitment to providing the best treatment options for people with cancer and we are delighted to be working alongside them on this.”


AKYNZEO® is already being marketed in the EU, the U.S., and several other leading markets of the world.

COMPANY
About Us
Promoters
Advertise With Us
Careers
Feedback / Contact Us
NEWS SECTIONS
Industry & Commerce
Fashion & Entertainment
Health
Politics
Sports
POLICIES
Copyright Policy
Terms of Use
Privacy Policy
Complaints
CONTACT INFORMATION
Bangalore News Network
General:
info@bangalorenewsnetwork.com
Complaints:
Complaints@bangalorenewsnetwork.com
Send Your Feedback Here
Copyright © 2003 Bangalore News Network.
Software by Probiz IT & ITES